Drug Overview

Sulfatinib is a modern cancer medication designed to attack tumors from multiple angles. It is a highly specialized pill that acts as a “Smart Drug” by targeting specific proteins that help cancer grow and hide from the body. In the medical world, it is known as a multi-kinase inhibitor. It is a primary example of Targeted Therapy because it focuses on the specific biological pathways used by tumors rather than attacking all fast-growing cells.

For patients and healthcare providers, sulfatinib offers a new way to treat rare tumors of the endocrine system. By blocking the blood supply to tumors and helping the immune system find cancer cells, it provides a dual-action defense against the spread of the disease.

• Generic name: Sulfatinib (also known as Surufatinib)
• US Brand names: None (Currently an investigational drug in the US; approved in other international markets like China)
• Drug Class: Tyrosine Kinase Inhibitor (TKI); Angiogenesis Inhibitor
• Route of Administration: Oral (Capsules taken by mouth)
• FDA Approval Status: Investigational (Currently in clinical trials in the US and Europe; has received Fast Track and Orphan Drug designations)

What Is It and How Does It Work? (Mechanism of Action)

Sulfatinib works by acting as a precision “off switch” for three specific proteins on the surface of cells. To understand how it works at the molecular level, we look at how it blocks the signals that tumors use to survive and multiply.

The drug targets three main receptors:

1. VEGFR (Vascular Endothelial Growth Factor Receptor): Tumors need their own blood vessels to get food and oxygen. Sulfatinib blocks the VEGFR proteins, which prevents the tumor from growing new blood vessels. This “starves” the tumor of the nutrients it needs to get bigger.
2. FGFR1 (Fibroblast Growth Factor Receptor 1): This protein sends a direct “grow and multiply” message to the cancer cell. By blocking FGFR1, the drug stops the tumor from dividing and spreading to other parts of the body.
3. CSF1R (Colony-Stimulating Factor 1 Receptor): This is where sulfatinib shows its “Immunotherapy” characteristics. Some immune cells, called macrophages, actually help tumors hide from the rest of the immune system. Sulfatinib blocks CSF1R, which reduces the number of these “bad” macrophages around the tumor. This allows the body’s natural T-cells to find and attack the cancer more effectively.

FDA-Approved Clinical Indications

As of 2026, sulfatinib is primarily used in international clinical trials and under specific regulatory approvals for rare tumors.

Oncological uses

• Treatment of advanced Extra-Pancreatic Neuroendocrine Tumors (epNETs), such as those found in the lungs or digestive tract.
• Treatment of advanced Pancreatic Neuroendocrine Tumors (pNETs).
• Investigational research for advanced biliary tract cancers.
• Research into combination therapies with other “Checkpoint Inhibitor” immunotherapies.

Non-oncological uses

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Sulfatinib is taken as an oral capsule once a day. It is important to take it at the same time every day to maintain a steady level of the drug in your system.

Dose Adjustments

For patients with hepatic (liver) insufficiency, the drug is used with caution. If liver enzymes in the blood rise, the doctor may lower the dose to 250 milligrams or 200 milligrams daily. For patients with renal (kidney) insufficiency, no standard starting adjustment is required, but kidney function is tracked closely throughout the treatment.

Clinical Efficacy and Research Results

Current clinical study data from 2020 to 2026 has shown that sulfatinib is very effective for patients with neuroendocrine tumors who have limited treatment options.

Numerical data from the SANET-ep and SANET-p Phase 3 trials showed that sulfatinib significantly increased “progression-free survival.” In patients with extra-pancreatic tumors, the drug nearly doubled the time the disease stayed stable compared to those not receiving the drug (9.2 months versus 3.8 months). In patients with pancreatic tumors, the results were even stronger, with a median progression-free survival of 10.9 months. Research results also indicate an “objective response rate” of approximately 10 percent to 20 percent, which is considered high for these rare and slow-growing types of cancer.

Safety Profile and Side Effects

Because sulfatinib blocks blood vessel growth and immune signals, it has a specific set of side effects that patients and doctors must manage.

Black Box Warning

There is no official Black Box Warning for sulfatinib, but it carries a strong warning for severe high blood pressure and potential bleeding.

Common side effects

These occur in more than 10 percent of patients:

• High blood pressure (hypertension)
• Protein in the urine (proteinuria)
• Diarrhea
• Feeling very tired (fatigue)
• Decreased appetite

Serious adverse events

• Severe bleeding (hemorrhage).
• Liver stress (indicated by very high liver enzymes in blood tests).
• Significant drop in white blood cell or platelet counts.
• Heart rhythm changes (monitored by EKG).

Management strategies

Most patients will need to take blood pressure medication while using sulfatinib. Doctors check the urine for protein before every cycle to ensure the kidneys are healthy. If diarrhea occurs, standard over-the-counter medicines are usually effective. If side effects become too strong, the doctor will pause the drug for a few days to let the body recover.

Research Areas

Sulfatinib is a major focus in Research Areas involving “Combination Targeted Therapy.” Scientists are studying if combining sulfatinib with modern Immunotherapy (like PD-1 inhibitors) can create a “double-strike” against tumors that have become resistant to other treatments. There is also interest in the field of regenerative medicine to see if blocking the CSF1R pathway helps the body’s natural stem cells rebuild healthy tissue after the tumor has been treated. Current 2025-2026 research is specifically looking at its use in pediatric rare tumors and advanced liver cancers.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Blood pressure check (must be controlled before starting).
• Comprehensive Metabolic Panel (CMP) to check liver and kidney function.
• Complete Blood Count (CBC).
• Urine test to check for baseline protein levels.
• Baseline EKG to check heart rhythm.

Precautions during treatment

You must monitor your blood pressure at home every day. Because the drug blocks new blood vessel growth, it can slow down wound healing. Tell your doctor if you have any planned surgeries or dental work.

Do’s and Don’ts list

• Do take your capsule on an empty stomach at the same time each day.
• Do keep a daily log of your blood pressure readings.
• Do use effective birth control, as this drug can be harmful to a developing baby.
• Don’t take a double dose if you miss one; just wait for your next scheduled time.
• Don’t take new herbal supplements without asking your oncologist first.
• Don’t ignore a sudden, severe headache or vision changes, as these could be signs of very high blood pressure.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Sulfatinib is a potent targeted therapy that must be managed by a qualified oncologist. Always consult with your healthcare provider regarding your specific diagnosis, treatment plan, and potential side effects.